Advertisement

Canine Liver Fibrosis Model to Assess the Functions of Infused Autologous Bone Marrow-Derived Cells

  • Taro Takami
  • Kenji Tani
  • Yasuho Taura
  • Isao Sakaida
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1905)

Abstract

Liver cirrhosis is the end stage of chronic liver disease, and the only radical treatment for decompensated liver cirrhosis is still liver transplantation. Development of effective regenerative therapy for liver cirrhosis is an urgent task. Before human clinical trials can be considered, the safety and efficacy of any planned protocol must be confirmed in medium-to-large animals. Therefore, we have developed a novel canine liver fibrosis model for proof of concept (POC) studies.

Key words

Liver cirrhosis Canine model Mesenchymal stem cells Carbon tetrachloride 

Notes

Acknowledgments

The development of this model was supported by the Japanese highway program for the realization of regenerative medicine of the Japan Science and Technology Agency (JST) and the Japan Agency for Medical Research and Development (AMED) and by JSPS KAKENHI grant numbers JP17H04162 to I.S. and JP17K09428 to T.T. We also thank the members involved in this model, Luiz Fernando Quintanilha, Takashi Matsuda, Bruno Diaz Paredes, Yuki Aibe, Ryo Sasaki, Tatsuro Nishimura, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Yasuhisa Oishi, Ikuyo Yoshida, Koushiro Ozono, Takafumi Kanematsu, Katsuhiro Kesamaru, Hironori Morisaki, Miku Yamashita, Yutaro Kitaura, Ko Nakasumi, Kazuaki Igari, Shotaro Eto, Kyosuke Hidari, Masahiro Imagawa, Tsunehiro Isozaki, Kentaro Itoh, Haruhi Sakai, Mai Sakai, Hiroya Inoue, Fumiya Yamane, Masato Hiyama, and Saori Shinzato.

References

  1. 1.
    Takami T, Terai S, Sakaida I (2012) Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol 28(3):203–208.  https://doi.org/10.1097/MOG.0b013e3283521d6aCrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Terai S, Sakaida I, Yamamoto N, Omori K, Watanabe T, Ohata S, Katada T, Miyamoto K, Shinoda K, Nishina H, Okita K (2003) An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem 134(4):551–558CrossRefGoogle Scholar
  3. 3.
    Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, Okita K (2004) Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40(6):1304–1311.  https://doi.org/10.1002/hep.20452CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I (2006) Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24(10):2292–2298.  https://doi.org/10.1634/stemcells.2005-0542. pii: 2005-0542CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kim JK, Park YN, Kim JS, Park MS, Paik YH, Seok JY, Chung YE, Kim HO, Kim KS, Ahn SH, Kim do Y, Kim MJ, Lee KS, Chon CY, Kim SJ, Terai S, Sakaida I, Han KH (2010) Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant 19(10):1237–1246.  https://doi.org/10.3727/096368910X506863CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kim JK, Kim SJ, Kim Y, Chung YE, Park YN, Kim HO, Kim JS, Park MS, Sakaida I, Kim DY, Lee JI, Ahn SH, Lee KS, Han KH (2017) Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis. Cell Transplant 26(6):1059–1066.  https://doi.org/10.3727/096368917X694778CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tanimoto H, Terai S, Taro T, Murata Y, Fujisawa K, Yamamoto N, Sakaida I (2013) Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow. Cell Tissue Res 354(3):717–728.  https://doi.org/10.1007/s00441-013-1727-2CrossRefPubMedGoogle Scholar
  8. 8.
    Quintanilha LF, Takami T, Hirose Y, Fujisawa K, Murata Y, Yamamoto N, Goldenberg RC, Terai S, Sakaida I (2014) Canine mesenchymal stem cells show antioxidant properties against thioacetamide-induced liver injury in vitro and in vivo. Hepatol Res 44(10):E206–E217.  https://doi.org/10.1111/hepr.12204CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Matsuda T, Takami T, Sasaki R, Nishimura T, Aibe Y, Paredes BD, Quintanilha LF, Matsumoto T, Ishikawa T, Yamamoto N, Tani K, Terai S, Taura Y, Sakaida I (2017) A canine liver fibrosis model to develop a therapy for liver cirrhosis using cultured bone marrow-derived cells. Hepatol Commun 1(7):691–703.  https://doi.org/10.1002/hep4.1071CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Taro Takami
    • 1
  • Kenji Tani
    • 2
  • Yasuho Taura
    • 2
  • Isao Sakaida
    • 1
  1. 1.Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of MedicineYamaguchi UniversityUbeJapan
  2. 2.Department of Veterinary Surgery, Joint Faculty of Veterinary MedicineYamaguchi UniversityYamaguchiJapan

Personalised recommendations